Abstract
The biology and clinical impact of bone marrow (BM) infiltration in patients with diffuse large B-cell lymphoma (DLBCL) remains unclear in the rituximab era. We retrospectively analyzed 232 patients diagnosed with DLBCL at our center between 1999 and 2014. Concordant-presence of large cells similar to those of the lymph node biopsy- and discordant-infiltration by small cells forming lymphoid aggregates, lacking cytological atypia-BM infiltration was defined by histological criteria and further characterized by flow cytometry (FCM). Cell of origin (COO) was determined using Hans’ algorithm. For the clonal relationship between tumor and discordant BM, the VDJH rearrangement was analyzed. Survival analyses were restricted to 189 patients treated with rituximab and chemotherapy. Thirty-six (16%) had concordant, and 37 (16%) discordant BM infiltration. FCM described different indolent lymphomas among discordant cases, clonally related with DLBCL in 10/13 available samples. Median follow-up was 58 months. 5-year-progression-free survival (PFS) for non-infiltrated, discordant and concordant groups was 68%, 65% and 30%, respectively (p < 0.001). Combining COO and BM infiltration, patients with discordant BM and non-germinal center B-cell COO also had decreased 5-year-PFS (41.9%). In multivariate analysis, concordant BM had an independent effect on PFS (HR 2.5, p = 0.01). Five-year cumulative incidence of central nervous system (CNS) relapse was 21%, 4% and 1% in concordant, discordant and non-infiltrated groups, respectively (p < 0.001). In conclusion, concordant BM infiltration represents a subset with poor prognosis, whereas the prognostic impact of discordant BM infiltration could be limited to non-CGB cases.
Highlights
Bone marrow (BM) is involved in 11–25% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) [1,2,3,4]
This finding is in accordance with the results reported by Sehn et al [2] from larger series and, in agreement with these observations, a recent study published by Yao et al [18] has suggested that patients with DLBCL and concordant BM involvement should be considered a distinct entity due to a more aggressive course and poor prognosis in terms of both progression free survival (PFS) and overall survival (OS)
BM involvement has been cited as a risk factor for central nervous system (CNS) involvement [8], a study performed in the rituximab era found that BM involvement was associated with a higher rate of CNS relapse only in the presence of increased LDH [7]
Summary
Bone marrow (BM) is involved in 11–25% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) [1,2,3,4]. Several studies indicate that low-grade histology in BM (discordant BM) is present in 30–50% of DLBCL patients with BM infiltration [1,2,3,4]. Previous work has shown the unfavorable prognosis determined by a concordant marrow infiltration, with lower progression free survival (PFS) and overall survival (OS) [1,2,3,4,6]. The prognostic role of discordant BM infiltration is unclear, but it seems to be less unfavorable than concordant involvement, as no study has proven that discordant BM is an independent prognostic factor for OS. The role of BM involvement as a risk factor for central nervous system (CNS)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
